Fintel reports that on November 10, 2025, Leerink Partners maintained coverage of uniQure N.V. (NasdaqGS:QURE) with a ...

Fintel reports that on November 10, 2025, Leerink Partners maintained coverage of Cogent Biosciences (NasdaqGS:COGT) with a ...

Cogent Biosciences expects to file a new drug application for bezuclastinib in gastrointestinal stromal tumors early next ...

Investing.com -- Eli Lilly shares were upgraded to Outperform at Leerink Partners, which cited “multiple waves of obesity treatment adoption drivers” and raised its price target to $1,104 from $886.

Pfizer’s third quarter results reflected ongoing challenges in its COVID-19 franchise, but management pointed to solid growth ...

Cogent Biosciences, Inc. (“Cogent”) (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for ...

Wall Street ended sharply higher on Monday, led by big gains in Nvidia, Palantir and other heavyweight AI-related companies ...

Companies don’t generally cut prices out of generosity.

Lilly will also gain certain rights to MeiraGTx’s proprietary riboswitch technology for use in gene editing in the eye. Under ...

Markets are coming back strong. All thanks to the news that the government shutdown may soon be over, which would remove a ...

Operator: Ladies and gentlemen, thank you for joining us today. And third quarter 2025 results conference call. At this time, ...

Detailed price information for Abcellera Biologics Inc (ABCL-Q) from The Globe and Mail including charting and trades.